Skip to main navigation
Logo

Live - Corprorate Menu

  • About Us
    • Our Leadership
    • Diversity, Equity, and Inclusion
    • Collaborations
    • Compliance and Ethics
    • Corporate Giving
  • Our Focus
    • Cerebral Adrenoleukodystrophy
    • Sickle Cell Disease
    • Transfusion Dependant Beta-Thalassemia
  • Our Science
    • Our Approach to Gene Therapy
    • Our Treatment Process
    • Our Pipeline
    • Clinical Trials
  • Patients & Advocacy
    • Patient Advocacy
    • Patient Resources
    • Access Policy

Live - Top Nav

  • investors & media
  • contact us
  • careers
  • stories

Investors & Media

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs

Toolkit

  • Annual Meeting
  • Information Request
  • Sign Up for Email Alerts
  • RSS Feeds

Media Contacts

  • Sarah Alspach

    Chief Communications Officer

    (857) 299-6198

    sarah.alspach@bluebirdbio.com

  • Jess Rowlands

    Senior Director, Product Communications

    (857) 299-6103

    jess.rowlands@bluebirdbio.com

Investor Contacts

  • Courtney O’Leary

    Investor Relations

    (978) 621-7347

    coleary@bluebirdbio.com

bluebird bio Secures $35M in Series B Funding

  • Read more about bluebird bio Secures $35M in Series B Funding

New Data From Adrenoleukodystrophy (ALD) Pilot Study Presented at American Society of Gene and Cell Therapy Show Three-Year Disease Stabilization of Patients

  • Read more about New Data From Adrenoleukodystrophy (ALD) Pilot Study Presented at American Society of Gene and Cell Therapy Show Three-Year Disease Stabilization of Patients

Genetix Pharmaceuticals Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer

  • Read more about Genetix Pharmaceuticals Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer

NATURE Publishes Promising Results on Treatment of First Patient in bluebird bio's Phase 1/2 Beta-Thalassemia Study

  • Read more about NATURE Publishes Promising Results on Treatment of First Patient in bluebird bio's Phase 1/2 Beta-Thalassemia Study

bluebird bio Awarded Two Qualifying Therapeutic Discovery Project Program Grants

  • Read more about bluebird bio Awarded Two Qualifying Therapeutic Discovery Project Program Grants

bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy

  • Read more about bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy

Massachusetts Life Sciences Center Announces 2010 Tax Incentives Targeted at

  • Read more about Massachusetts Life Sciences Center Announces 2010 Tax Incentives Targeted at

bluebird bio Awarded up to $4.2 Million from the French Muscular Dystrophy Association for Continued Development of Gene Therapy for Beta-Thalassemia and Sickle Cell Anemia

  • Read more about bluebird bio Awarded up to $4.2 Million from the French Muscular Dystrophy Association for Continued Development of Gene Therapy for Beta-Thalassemia and Sickle Cell Anemia

bluebird bio Appoints World Leading Experts to Inaugural Scientific Advisory Board

  • Read more about bluebird bio Appoints World Leading Experts to Inaugural Scientific Advisory Board

bluebird bio Adds Biotech Industry Veterans to Management Team and Board

  • Read more about bluebird bio Adds Biotech Industry Veterans to Management Team and Board

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 35
  • Page 36
  • Page 37
  • Page 38
  • Page 39
  • Current page 40
  • Page 41
  • Page 42
  • Page 43
  • Next page Next ›
  • Last page Last »
Subscribe to

Quick Links

  • Patients & Advocacy
  • Investors & Media
  • Careers
  • Contact Us

CONTACT INFO

info@bluebirdbio.com

clinicaltrials@bluebirdbio.com

investor@bluebirdbio.com

medinfo@bluebirdbio.com

Live - Terms & Privacy

  • Terms of Service
  • Privacy Policy
  • Cookie Notice
  • Sitemap
© 2022 bluebird bio, Inc. All Rights Reserved. Corp-US-00175 04/22

Live - Social Links